Highly contagious negative strand RNA paramyxo virus that is transmitted via the respiratory route and causes systemic disease in previously unexposed humans and non-human primates.
Enveloped virus with a single strand, non-segmented negative sense RNA genome
Exclusively causes disease in old- and new-world non-human primates (NHPs) and humans
Genus: Morbillivirus (all morbilliviruses are highly contagious and is transmitted via the respiratory route)
Epidemiology
No animal reservoir and occurs only in humans.
90% secondary attack rate
Pathophysiology
The inhaled virus from the exposed droplets initially infects the respiratory tract’s lymphocytes, dendritic cells, and alveolar macrophages. It then spreads to the adjacent lymphoid tissue and disseminates throughout the bloodstream resulting in viremia and spread to distant organs. The virus residing in the dendritic cells and lymphocytes transfers itself to the epithelial cells of the respiratory tract which are shed and expelled as respiratory droplets during coughing and sneezing, infecting others and perpetuating the cycle.
Clinical features
Incubation period:
MeV infection starts with an incubation period, during which the virus replicates primarily in myeloid and lymphoid cells and establishes a systemic infection.
Prodromal stage:
After 7–14 days, when MeV has spread to the peripheral lymphoid tissues, a prodromal phase starts with malaise, fever and cough. At that point, infected lymphocytes have disseminated the virus to peripheral tissues, including the skin and the submucosa of the respiratory tract, and have transmitted MeV to epithelial cells and keratinocytes.
Fever & malaise
Three Cs: Cough, coryza and conjunctivitis
Koplik’s spots (PATHOGNOMIC and appear 1-2 days before the rash): Small white papules on buccal mucosa (behind 2nd & 3rd molar)
Can occur in conjuncativa or vaginal mucosa
Maculopapular rash:
The maculopapular skin rash appears 3–5 days after the prodromal phase and coincides with the appearance of MeV-specific humoral and cellular immune responses. The rash usually starts behind the ears or on the face and spreads to the trunk and extremities. Conjunctivitis appears around the same time and often results in photophobia. Both rash and conjunctivitis are caused by immune-mediated clearance of MeV-infected cells and may be absent in immunodeficient patients, making the disease difficult to recognize in this patient group
Rash appears on 4th day of fever, commonly the retroauricular space and spreads to the face, trunk and extremities
Complications
HALLMARK of measles is the transient immune suppression, leading to increased susceptibility to opportunistic infections. At the same time, the disease is paradoxically associated with induction of a robust virus-specific immune response, resulting in lifelong immunity to measles.
Immune suppression:
In uncomplicated measles cases, clinical signs usually start to fade a few days after the onset of rash and patients recover in approximately 1 week. By contrast, measles-associated immune suppression, which coincides with widespread epithelial damage, increases susceptibility to secondary bacterial infections that can result in complications, such as diarrhoea, pneumonia or otitis media
Hecht giant cell pneumonia (due to measles itself)
Warthin-Finkeldey cells (multinucleated giant cells/syncytia) (PATHOGNOMIC): Fused B-cells found in lymphoid tissues in the upper respiratory tract
Secondary bacterial infection:
Diarrhoea
Pneumonia: M/C cause of death
Otitis media: M/C complication
Long-term CNS complications:
Recovery is followed by lifelong immunity to measles. In rare cases, severe measles-associated central nervous system (CNS) complications may develop:
Acute disseminated encephalomyelitis (ADEM): Autoimmune demyelinating disease that occurs within days to weeks
Measles inclusion body encephalitis (MIBE): Progressive brain infection in patients with impaired cellular immunity occurring within months of the initial infection.
Subacute sclerosing panencephalitis (SSPE): Progressive neurological disease that presents 5-10 years after the acute illness and thought to be caused by an abnormal host response to the production of mutated virions
Measles during pregnancy:
MeV infection during pregnancy increases the risk of maternal, fetal and neonatal complications; it can damage the placenta and/or fetus and lead to spontaneous termination, stillborn birth or live birth of infants with congenital measles
Maternal death
Spontaneous abortion
Intrauterine fetal death
Low birth-weight infant
Diagnosis
The diagnosis of measles hinges on a high clinical suspicion, especially when evaluating children with febrile illness and a maculopapular rash.
Reverse transcription PCR (RT-PCR)
Detection of anti-MeV IgM antibodies or MeV RNA
Plaque reduction neutralization assay:
gold standard test with the highest sensitivity.
Differential diagnosis:
Other viral illnesses associated with rash
Chicken pox: Appears on 1st day of fever, with centripetal distribution and pleomorphic appearance like dewdrops on a rose petal.
Erythema infectiosum: Rash on cheeks (slapped cheek appearance), and moves to trunk and extremities
Erythema subitum: Macules/maculopapular rash
Infectious mononucleosis: Associated with maculopapular rash
Rubella (German measles)
Roseola
Management
Treatment of uncomplicated measles cases typically involves supportive care, including antipyretics, antitussives, hydration and/or environmental controls (for example, humidification).
Trivalent measles-mumps-rubella (MMR) vaccine:
Administered in 2 doses with children most often receiving the first dose around 1 year of age and the second dose typically given between the ages of 4 to 6
One reply on “Measles”
[…] (M/C): Post-pneumonia, whooping cough, measles, mycobacterial […]